Forest Investigative Site 062 — Erie, Pennsylvania

Forest Investigative Site 062 is a clinical research site located in Erie, Pennsylvania, United States 16506.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

Forest Investigative Site 062 has participated in 1 clinical trials.

Therapeutic areas: COPD, COPD Exacerbation, Lung Diseases.

Sponsors: AstraZeneca.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Forest Investigative Site 062?

Forest Investigative Site 062 has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Forest Investigative Site 062 conducted?

Forest Investigative Site 062 has 1 clinical trials on record. Their work covers COPD, COPD Exacerbation, Lung Diseases.

Is Forest Investigative Site 062 accredited by Crixeo Health?

Forest Investigative Site 062 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Forest Investigative Site 062?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.